![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The liver function was studied in 15 patients before and during treatment with cefuroxime. Four elderly patients had a prolonged half-life of galactose at admission but they all showed declining values during the cefuroxime treatment. Only in one patient did the galactose half-life increase during treatment (from 14 to 25 min). This patient was an old diabetic who also had prostatic cancer. Cefuroxime treatment seems to be well tolerated also in patients with signs of impaired metabolic liver function at start of treatment.